Trial Profile
Long term efficacy, safety and tolerability (>24 Months) of twice daily dosing of deferasirox in transfusion dependent thalassemias who were unresponsive to standard once daily dose
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2016
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Thalassaemia
- Focus Therapeutic Use
- 02 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology